Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.…
Callio Therapeutics Appoints Chris Hassig, PhD, as Chief Scientific Officer
Boundless Bio (NASDAQ: BOLD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 28 employees.
The shares were at 2.320 USD on 20 November 2026, up 88.6% over 52 weeks. Its 52-week range is 0.9610 USD to 3.164 USD: the price is 26.7% below the high and 141.4% above the low.
Its market capitalisation is 54.78M USD.
Boundless Bio reports return on equity of -59.0% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 62.89M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. One analyst covers the stock, with an average rating of Hold; their mean price target of 4.000 USD is 72.4% above the current price.